In renal cell carcinoma, small cell lung cancer and melanoma, the microbiota can alter the response to immunotherapy via antibodies targeting programmed cell death protein-1 (PD-1) or its ligand (PDL-1) [17–19]. Here, PDCD1 is linked to renal cell carcinoma.